Review
doi: 10.1016/j.bpg.2006.04.004.
Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET
Affiliations
- PMID: 16997171
- DOI: 10.1016/j.bpg.2006.04.004
Item in Clipboard
Review
Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET
Best Pract Res Clin Gastroenterol.
2006.
Abstract
Neoadjuvant or adjuvant multimodality therapy in oesophageal cancer is introduced in an effort to improve prognosis. However, in a substantial fraction of patients there is no response to this non-surgical therapy. Non-invasive imaging modalities such as computed tomography (CT), endoscopic ultrasound (EUS) and 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) have been evaluated for assessing patient response to therapy, and these are described in this review. Currently, FDG-PET seems to be the best available tool for neoadjuvant therapy response assessment in oesophageal cancer.
Similar articles
-
The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.J Thorac Cardiovasc Surg. 2005 Jun;129(6):1232-41. doi: 10.1016/j.jtcvs.2004.12.042. J Thorac Cardiovasc Surg. 2005. PMID: 15942562
-
Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer? A prospective single center study.Am J Gastroenterol. 2008 Mar;103(3):570-4. doi: 10.1111/j.1572-0241.2007.01579.x. Epub 2007 Oct 17. Am J Gastroenterol. 2008. PMID: 17941963
-
Staging in oesophageal cancer.Best Pract Res Clin Gastroenterol. 2006;20(5):877-91. doi: 10.1016/j.bpg.2006.05.001. Best Pract Res Clin Gastroenterol. 2006. PMID: 16997167 Review.
-
18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.J Nucl Med. 2009 May;50 Suppl 1:89S-96S. doi: 10.2967/jnumed.108.057232. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380406 Review.
-
The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography.Gastrointest Endosc. 2007 Mar;65(3):377-84. doi: 10.1016/j.gie.2006.12.015. Gastrointest Endosc. 2007. PMID: 17321235 Clinical Trial.
Cited by
-
Change in Density Not Size of Esophageal Adenocarcinoma During Neoadjuvant Chemotherapy Is Associated with Improved Survival Outcomes.J Gastrointest Surg. 2022 Dec;26(12):2417-2425. doi: 10.1007/s11605-022-05422-w. Epub 2022 Oct 10. J Gastrointest Surg. 2022. PMID: 36214951
-
NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).BMC Med Phys. 2008 Jul 31;8:3. doi: 10.1186/1756-6649-8-3. BMC Med Phys. 2008. PMID: 18671847 Free PMC article.
-
Difference in Computed Tomography Image Quality between Central Vein and Peripheral Vein Enhancement in Treatment Naive Esophageal Cancer Patients.Cancers (Basel). 2021 Aug 19;13(16):4172. doi: 10.3390/cancers13164172. Cancers (Basel). 2021. PMID: 34439325 Free PMC article.
-
Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.Clin Cancer Res. 2019 Oct 15;25(20):6170-6179. doi: 10.1158/1078-0432.CCR-19-0318. Epub 2019 Jul 29. Clin Cancer Res. 2019. PMID: 31358543 Free PMC article.
-
Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?World J Gastroenterol. 2008 May 7;14(17):2691-701. doi: 10.3748/wjg.14.2691. World J Gastroenterol. 2008. PMID: 18461654 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
